Regeneron Pharmaceuticals, Inc. · NASDAQ:REGN
Murphy Andrew J sold 5,011 Regeneron Pharmaceuticals, Inc. shares (Form 4)
Traded Nov 16 to Nov 17, 2026 · Filed Nov 18, 2026
From Nov 16 to Nov 17, 2026, Murphy Andrew J (Co-Chief Scientific Officer) sold 5,011 Regeneron Pharmaceuticals, Inc. shares at an average US$957.76 for US$4.8M under a trading plan, leaving 46,779 shares. Filed Nov 18, 2026 (Form 4).
- Sold
- 5,011 shares
- Price
- US$957.76 average (US$949.69 to US$964.36)
- Value
- US$4.8M
- Holding after
- 46,779 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Co-Chief Scientific Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Nov 16, 2026 | Common Stock | Option exercise | 17,000 | US$381.92 | 63,779 | Direct |
| Nov 16, 2026 | Common Stock | Shares withheld for tax | 11,989 | US$960.02 | 51,790 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 93 | US$949.69 | 51,697 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 74 | US$950.61 | 51,623 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 298 | US$951.75 | 51,325 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 220 | US$952.75 | 51,105 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 671 | US$953.69 | 50,434 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 313 | US$954.45 | 50,121 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 313 | US$955.48 | 49,808 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 346 | US$956.70 | 49,462 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 202 | US$957.53 | 49,260 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 244 | US$958.27 | 49,016 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 506 | US$959.45 | 48,510 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 257 | US$960.65 | 48,253 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 584 | US$961.45 | 47,669 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 295 | US$962.70 | 47,374 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 255 | US$963.60 | 47,119 | Direct |
| Nov 17, 2026 | Common Stock | Sale | 340 | US$964.36 | 46,779 | Direct |
Source
Download original · View original at SEC
Related
- Regeneron Pharmaceuticals, Inc.
- Murphy Andrew J
- Regeneron Pharmaceuticals, Inc. shareholders
- Form 4 · Murphy Andrew J · Nov 5, 2026
- Form 4 · Murphy Andrew J · Oct 15, 2026
- Form 4 · Sing George L · Nov 18, 2026
- Form 4 · McCourt Marion · Nov 18, 2026
- Form 4 · Pitofsky Jason · Nov 6, 2026
- Schedule 13G · Vanguard Capital Management LLC · Apr 30, 2026
- Schedule 13G/A · The Vanguard Group · Mar 27, 2026